Clinical Trials on Risk Assessment in Hungary

Total 17 results

Sanofi

Terminated

Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line

Thrombosis Prophylaxis (Risk of Thrombosis Due to Central Venous Line (CVL)

Hungary
AstraZeneca

Completed

C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS) (C2 -CORVUS)

Cardiovascular Risk

Hungary
University of Oxford
British Heart Foundation; European Commission; Oxford University Hospitals NHS... and other collaborators

Recruiting

The Oxford Risk Factors And Non-Invasive Imaging Study (ORFAN)

Cardiovascular Diseases | Cardiovascular Risk Factors

United Kingdom, Germany, Belgium, China, United States, Australia, France, Greece, Hungary, Italy, Japan, Korea, Republic of, Netherlands, Romania, United Arab Emirates
Hendrik Streeck
Janssen, LP

Completed

Prospective Observational Cohort HIV & STI Study in Europe

HIV Infections | Sexual Behavior | HIV-1-infection | Risk Reduction

France, Hungary, Spain, Poland, Italy
Baxter Healthcare Corporation
Apatech, Inc.

Completed

Performance of Inductigraft in Spinal Fusion (APOLLO)

Spinal Stenosis of Lumbar Region | Degenerative Disk Disease

Ireland, Germany, Spain, United Kingdom, Hungary
Sanofi
Bristol-Myers Squibb

Completed

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

Atrial Fibrillation | Vascular Risk

United States, France, Canada, Brazil, Poland, Australia, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Malaysia, Singapore, Taiwan, Belgium, Czech Republic, Mexico, Argentina, Denmark, Finland, Hungary, Norway, United... and more
Sanofi
Bristol-Myers Squibb

Terminated

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)

Atrial Fibrillation | Vascular Risk

United States, France, Canada, Brazil, Poland, Russian Federation, Australia, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey, Malaysia, Singapore, Taiwan, Belgium, Czech Republic, Mexico, Denmark, Finland, H... and more
The Medicines Company

Completed

Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol (ORION-11)

Risk Factor, Cardiovascular | Elevated Cholesterol | ASCVD

Germany, Czechia, Hungary, Poland, South Africa, Ukraine, United Kingdom
Novartis Pharmaceuticals

Terminated

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. (ReTHINK)

Myelofibrosis With High Molecular Risk Mutations

Belgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
ECRI bv
University of Bern; European Cardiovascular Research Center; Terumo Medical Corporation and other collaborators

Completed

Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen (MASTER DAPT)

Coronary Artery Disease | PCI | High Bleeding Risk

Netherlands, France, United Kingdom, Australia, Singapore, Japan, Italy, Poland, Spain, Switzerland, Israel, Argentina, Austria, Bahrain, Bangladesh, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, India, Korea, Republic... and more
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

CANVAS - CANagliflozin cardioVascular Assessment Study (CANVAS)

Cardiovascular Diseases | Diabetes Mellitus, Type 2 | Risk Factors

United States, Australia, Poland, Ukraine, United Kingdom, Belgium, Germany, France, Spain, Argentina, Colombia, Israel, Mexico, India, Canada, Netherlands, Sweden, Malaysia, New Zealand, Estonia, Russian Federation, Hungary, Norway, ... and more
Bayer

Active, not recruiting

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer (OASIS-4)

Hot Flashes | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

Spain, France, Belgium, United Kingdom, Hungary, Israel, Italy, Ireland, Germany, Portugal, Finland, Poland, Romania, Canada, Austria, Kazakhstan
AstraZeneca
The Cleveland Clinic; IQVIA RDS Inc.

Completed

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)

Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)

United States, Belgium, Italy, Netherlands, Denmark, Taiwan, Poland, Russian Federation, Korea, Republic of, Hungary, United Kingdom, China, New Zealand, Czechia, Australia, South Africa, Ukraine, Japan, Canada, Mexico, Lithuania, Estoni...
AstraZeneca
Bristol-Myers Squibb; Hadassah Medical Organization; The TIMI Study Group

Completed

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)

Diabetes Mellitus, Non-Insulin-Dependent | High Risk for Cardiovascular Event

United States, Canada, France, Italy, Netherlands, Spain, Belgium, Thailand, Vietnam, Bulgaria, Korea, Republic of, Brazil, Philippines, Russian Federation, Turkey, Taiwan, Australia, Israel, South Africa, Germany, Japan, Czechia, H... and more
Bayer

Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke (OCEANIC-STROKE)

Acute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic Attack

United States, Switzerland, Belgium, Sweden, Canada, Australia, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, Greece, Japan, Turkey, Netherlands, Romania, China, United Kingdom, Portugal, Italy, Brazil, France, Slovakia, ... and more
Novo Nordisk A/S

Recruiting

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (ZEUS)

Inflammation | Chronic Kidney Disease | Cardiovascular Risk

Korea, Republic of, Italy, United States, Spain, China, Taiwan, Mexico, Netherlands, Latvia, Malaysia, Thailand, Hungary, Australia, Poland, South Africa, India, Canada, Portugal, Romania, United Kingdom, Bulgaria, Germany, Brazil, Sw... and more
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

High-risk Non-muscle Invasive Bladder Cancer

Canada, Belgium, United States, Australia, Austria, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, China, Brazil, Colombia, ... and more

Clinical Trials on Risk Assessment in Hungary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations